Takeda Pharmaceutical Company Limited

Introduction
Takeda Pharmaceutical Company Limited is the largest pharmaceutical company in Japan and one of the top global biopharmaceutical firms. Founded in 1781, Takeda has grown from a traditional Japanese medicine business into a multinational leader in oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines. With a legacy spanning more than two centuries, Takeda is recognized for its deep commitment to innovation, patient care, and global health.

Mission and Vision

Mission: To strive toward better health and a brighter future for people worldwide through leading innovation in medicine.
Vision: To be a trusted, values-based global biopharmaceutical leader delivering transformative treatments to patients.

Products and Services

Oncology: Innovative therapies for hematologic cancers and solid tumors.
Gastroenterology: Treatments for inflammatory bowel disease (IBD), acid-related disorders, and liver diseases.
Neuroscience: Medicines for psychiatric, neurological, and sleep disorders.
Rare Diseases & Plasma-Derived Therapies: Specialized treatments for genetic and blood-related conditions.
Vaccines: Development of vaccines for dengue, norovirus, and other infectious diseases.
Other Areas: Expanded through partnerships and research in gene and cell therapy.

Growth and Innovation
Takeda strengthened its global presence with the $62 billion acquisition of Shire plc in 2019, significantly expanding into rare diseases and plasma-derived therapies. The company invests heavily in R&D, focusing on biologics, gene therapy, and next-generation vaccines. Takeda also embraces digital transformation and data science to accelerate drug discovery and patient access.

Global Impact
With operations in more than 80 countries, Takeda plays a key role in global health. The company is committed to equitable access to medicines, including its dengue vaccine rollout in Asia and Latin America. Takeda has a strong focus on sustainability, aiming for carbon neutrality and expanding healthcare access in underserved regions.